Giant cell tumor of bone: a neoplasm or a reactive condition?
Giant cell tumor of bone (GCTB) is a benign but locally aggressive bone tumor of young adults. It typically presents as a large lytic mass at the end of the epiphysis of long bones. Grossly it is comprised of cystic and hemorrhagic areas with little or no periosteal reaction. Microscopically areas of frank hemorrhage, numerous multinucleated giant cells and spindly stromal cells are present. Telomeric fusions, increased telomerase activity and karyotypic aberrations have been advanced as a proof of its neoplastic nature. However such findings are not universal and can be seen in rapidly proliferating normal cells as well as in several osseous lesions of developmental and/or reactive nature, and the true neoplastic nature of GCTB remains controversial. The ancillary studies have generally not reached to the point where these alone can be taken as sole diagnostic and discriminatory criteria. While giant cells and stromal cells have been extensively studied, little attention has been paid to the overwhelming hemorrhagic component. If examined carefully intact and partially degenerated red blood cells are almost invariably seen in many giant cells as well as in the stroma. While hemorrhage in many patients may be resolved without leaving any trace over time, in some it gives rise to giant cell formation, and in others it may lead to proliferation of fibroblasts and histiocytes. At times one sees xanthomatous cells due to intracytoplasmic cholesterol deposits and sharp cholesterol clefts. Individual genetic makeup, local tissue factors as well as the amount of hemorrhage may play a key role in the final effects and outcome. Malignancy usually does not occur in GCTB and when discover, it usually represents primary bone sarcomas missed at original diagnosis. Embolization therapy to curtail hemorrhage and insertion of cement substance to support matrix are helpful in reducing recurrences. Aneurysmal bone cyst (ABC) shares many features with GCTB. There had been unique karyotypic changes in some aneurysmal bone cysts making it distinct from GCTB. However these changes may be in the endothelial cells which are quite different from stromal or giant cells. It had been concluded that the poor matrix support to the vessels may lead to frequent and profuse intraosseous hemorrhage attracting blood-derived monocytes with active conversion into osteoclasts, resulting in GCTB formation. On the other hand, dilatation of the thin-walled blood vessels results in formation of ABCs. If hemorrhagic foci are replaced by proliferation of fibroblasts and histiocytes, then a picture of fibrous histiocytic lesion is emerged. Enhanced telomerase activity and karyotypic aberrations may be necessary for rapid division of the nuclei of the giant cells in order to be able to deal with significant in situ intraosseous hemorrhage.
Haque
Anwar Ul
AU
Department of Pathology, Pakistan Institute of Medical Sciences Islamabad, Pakistan. haque_8888@hotmail.com
Moatasim
Ambreen
A
Bone. 1995 Aug;17(2 Suppl):87S-91S
8579904
Calcif Tissue Int. 1980;31(1):29-34
6770971
Endocrinology. 1986 Feb;118(2):824-8
3455914
J Bone Joint Surg Br. 1992 Sep;74(5):652-8
1527108
Veroff Pathol. 1984;122:1-195
6091360
Virchows Arch B Cell Pathol. 1973 Mar 30;12(4):318-29
4196329
Am J Pathol. 1994 Oct;145(4):856-67
7943176
Science. 1980 May 2;208(4443):516-8
6154315
Endocrinol Jpn. 1990 Oct;37(5):741-7
2086204
Nature. 1961 Apr 29;190:459-60
13777407
Cancer Genet Cytogenet. 1996 May;88(1):35-8
8630976
Clin Orthop Relat Res. 2005 Sep;438:116-22
16131879
Int J Clin Exp Pathol. 2008 Jan 01;1(1):84-90
18784826
J Interferon Res. 1987 Oct;7(5):619-26
3479501
Mod Pathol. 2004 May;17(5):518-25
15044915
J Pathol. 1984 Dec;144(4):281-94
6520652
Curr Top Pathol. 1989;79:125-50
2644082
Recent Prog Horm Res. 1989;45:507-27; discussion 527-31
2682847
Clin Orthop Relat Res. 1976 Oct;(120):201-31
975659
Kathmandu Univ Med J (KUMJ). 2003 Jul-Sep;1(3):190-2
16388229
Calcif Tissue Int. 1997 Jan;60(1):63-70
9030482
Pediatr Dev Pathol. 2006 Jan-Feb;9(1):38-43
16808643
Lab Invest. 1992 Aug;67(2):166-74
1501443
Diagn Cytopathol. 2002 Dec;27(6):375-8
12451570
Nature. 1975 Nov 27;258(5533):325-7
1196357
Mod Pathol. 2000 Nov;13(11):1206-10
11106078
Int J Oral Surg. 1984 Apr;13(2):92-100
6430822
Mund Kiefer Gesichtschir. 2004 Sep;8(5):316-21
15480872
Pathobiology. 2002-2003;70(6):333-42
12865629
Clin Orthop Relat Res. 1997 May;(338):205-14
9170381
J Bone Joint Surg Am. 1976 Jul;58(5):612-8
932060
Endocrinology. 1991 May;128(5):2324-35
1850350
Ann Rheum Dis. 1996 Jun;55(6):388-95
8694579
J Postgrad Med. 1995 Jul-Sep;41(3):83-4
10707722
Ultrastruct Pathol. 2006 May-Jun;30(3):151-8
16825116
Hand Clin. 2004 Aug;20(3):269-81, vi
15275686
J Bone Miner Res. 2000 Apr;15(4):640-9
10780856
Horm Metab Res. 1987 Nov;19(11):585-9
2828212
Oncol Rep. 2006 Mar;15(3):589-94
16465417
Br J Cancer. 1992 Apr;65(4):523-6
1562461
Endocrinology. 1994 Jun;134(6):2416-23
8194468
Endocrinology. 1998 Oct;139(10):4353-63
9751519
Am J Pathol. 2004 Nov;165(5):1773-80
15509545
Science. 1975 Nov 21;190(4216):784-5
1105786
J Bone Miner Res. 1989 Feb;4(1):29-35
2541600
Proc Natl Acad Sci U S A. 1990 Sep;87(18):7260-4
2169622
Hum Pathol. 2005 Sep;36(9):945-54
16153456
J Clin Endocrinol Metab. 1978 Mar;46(3):425-33
87400
Proc Natl Acad Sci U S A. 1995 May 9;92(10):4562-6
7753843
Br J Oral Maxillofac Surg. 1993 Apr;31(2):89-94
8471587
Science. 1973 May 25;180(4088):875
4706681
J Bone Miner Res. 1996 Jan;11(1):62-71
8770698
Cancer. 1988 Sep 15;62(6):1139-45
2457425
J Clin Invest. 1994 May;93(5):1959-67
8182127
Fetal Pediatr Pathol. 2006 Sep-Oct;25(5):241-8
17438664
Clin Orthop Relat Res. 1986 Mar;(204):59-75
3006962
J Bone Miner Res. 1994 Jul;9(7):1123-30
7942160
Bosn J Basic Med Sci. 2007 Feb;7(1):58-65
17489771
Endocr Rev. 1992 Feb;13(1):66-80
1555533
J Cell Sci Suppl. 1986;4:267-86
3528195
J Cancer Res Clin Oncol. 1993;119(5):301-3
8440744
J Orthop Res. 2005 Jan;23(1):203-9
15607894
J Pathol Bacteriol. 1966 Jul;92(1):163-7
5956253
Ann Surg Oncol. 2007 Oct;14(10):2896-902
17653593
N Engl J Med. 1995 Dec 28;333(26):1757-63
7491141
Histol Histopathol. 2001 Jan;16(1):297-307
11193206
Am J Pathol. 2005 Jul;167(1):117-28
15972958
Acta Cytol. 1990 Nov-Dec;34(6):863-7
2256421
Pathology. 1999 Nov;31(4):373-8
10643009
J Bone Miner Res. 1992 May;7(5):555-61
1615762
Pathol Res Pract. 1999;195(11):753-7
10605695
Endocrinology. 1990 May;126(5):2733-41
2184023
Hum Pathol. 2003 Oct;34(10):983-93
14608531
Endocrinology. 1989 Jul;125(1):20-7
2544401
Cancer. 1995 Mar 1;75(5):1094-9
7850706
Nihon Seikeigeka Gakkai Zasshi. 1994 May;68(5):407-14
7914219
J Clin Pathol. 1992 May;45(5):398-404
1597517
Cell Tissue Res. 1985;241(3):671-5
2992797
J Oral Maxillofac Surg. 1999 Jul;57(7):848-53
10416634
J Cell Biochem. 1998 Jul 1;70(1):121-9
9632113
J Cell Sci. 1984 Aug;70:61-71
6501437
Cancer. 1990 Jun 15;65(12):2697-703
2340469
J Exp Med. 1975 Sep 1;142(3):651-63
1100763
J Assoc Physicians India. 2004 Jul;52:585-6
15645990
J Oral Maxillofac Surg. 1986 Sep;44(9):708-13
3462363
Life Sci. 2003 Aug 1;73(11):1427-36
12850503
J Pathol. 1987 Oct;153(2):121-6
2961857
Endocrinology. 1988 Apr;122(4):1373-82
3345718
J Pathol. 1985 Apr;145(4):297-305
2987469
N Engl J Med. 1974 Nov 14;291(20):1041-6
4413338
J Bone Joint Surg Am. 1990 Feb;72(2):252-8
1968067
J Endocrinol. 1969 Nov;45(3):387-400
5358264
J Bone Miner Res. 1994 Jul;9(7):1013-20
7942147
J Bone Miner Res. 2006 Sep;21(9):1339-49
16939392
Cancer Res. 1987 Aug 1;47(15):4141-5
3300960
Int Orthop. 2006 Dec;30(6):484-9
17013643
Lab Invest. 1994 Oct;71(4):465-71
7526033
Am J Pathol. 1986 Feb;122(2):363-78
3946557
Endocrinology. 1990 Jun;126(6):3153-8
2161750
Diagn Cytopathol. 2004 Jan;30(1):14-8
14696139
J Cell Sci. 1992 Mar;101 ( Pt 3):681-6
1522150
Pathol Res Pract. 1984 May;178(5):431-40
6462948
J Bone Miner Res. 1991 Feb;6(2):183-9
2028836
Cancer Genet Cytogenet. 2005 May;159(1):32-6
15860354